News

2026-10-15

Article published on Alzinova’s participation at the CTAD conference

Longevity.Technology has published an article about Alzinova and the company’s participation at the CTAD conference. The article highlights Alzinova’s Alzheimer’s vaccine candidate, ALZ-101, and the Phase II ADVANCE trial, which will be presented at the 19th Clinical Trials on Alzheimer’s…

Read more
Image for CEO Tord Labuda, was interviewed by The Harlem Times

2026-10-14

CEO Tord Labuda, was interviewed by The Harlem Times

The Harlem Times is now turning its attention to science. They reached out to CEO Tord Labuda to discuss… Read more
Image for DNB Carnegie: ALZ-101 enters Phase II start-up as Alzinova raises capital

2026-09-11

DNB Carnegie: ALZ-101 enters Phase II start-up as Alzinova raises capital

Alzinova has initiated operational preparations for the global Phase II study of ALZ-101, and also announced a SEK51m rights… Read more
Image for Redeye: Phase II study update and SEK51 rights issue

2026-09-11

Redeye: Phase II study update and SEK51 rights issue

Redeye comments on Alzinova’s announcements of the operational start-up of the global Phase II study for ALZ-101 and a… Read more
Image for GoCo Investor Day Sep 15

2026-09-04

GoCo Investor Day Sep 15

Alzinova participated in the Investor Day at CoGo Health Innovation City on September 15. GoCo Investor Day offers an… Read more
Image for BioStock: BioVal analysis Alzinova July 2026

2026-07-08

BioStock: BioVal analysis Alzinova July 2026

Read the brand new analyses from BioStock. The analysis provides an independent review of the scientific rationale, market opportunity… Read more
Image for Stopping Neurodegeneration with Precision Vaccines

2026-06-24

Stopping Neurodegeneration with Precision Vaccines

Can vaccines stop neurodegeneration before irreversible damage occurs? In an interview with Inside Precision Medicine, Alzinova CEO Tord Labuda… Read more
Image for Alzheimer panel discussion

2026-05-20

Alzheimer panel discussion

CEO, Tord Labuda, participated in BioStock’s Market Signal, a studio format focused on key trends and developments in the… Read more
Image for Interview: Q1 report, TO4 and the road to phase II

2026-05-19

Interview: Q1 report, TO4 and the road to phase II

Our CEO, Tord Labuda in an interview with BioStock talking about the Q1 report, TO4 and the road to… Read more
Image for Interview with CEO Tord Labuda

2026-04-28

Interview with CEO Tord Labuda

CEO Tord Labuda comments on the financing situation, the TO4 warrants, the dialogues with international partners and the plans… Read more
Image for Alzinova takes the requirement for precision one step further

2026-04-24

Alzinova takes the requirement for precision one step further

Read the latest interview with our CEO Tord Labuda… Read more
Image for Alzheimer’s disease remains one of the greatest healthcare challenges

2026-03-31

Alzheimer’s disease remains one of the greatest healthcare challenges

We are now preparing for the next phase of development, evaluating ALZ-101 in a larger patient population, an important… Read more
Image for Biostock interview

2026-03-31

Biostock interview

Our CEO Tord Labuda sums up the intensive conference period with the aim of partner agreements. Read more
Image for New CEO interview – Alzinova gears up for Phase II with secured financing

2026-03-05

New CEO interview – Alzinova gears up for Phase II with secured financing

Read more
Image for Our CSO Anders Sandberg interviewed by DNB Carnegie

2026-02-25

Our CSO Anders Sandberg interviewed by DNB Carnegie

CSO and co-founder Anders Sandberg talks about ALZ-101 and the scientific basis behind Alzinova's vaccine strategy against Alzheimer's disease. Read more
Image for BioStock Investor Pitch: Alzinova

2026-02-11

BioStock Investor Pitch: Alzinova

Alzinova’s CEO Tord Labuda recently joined BioStock’s studio to present the Company’s path forward, including preparations for the planned… Read more
Image for Alzinova presented at Redeye Investor Forum

2026-01-30

Alzinova presented at Redeye Investor Forum

Our CFO, Erik Kullgren, and VP R&D Projects, Stefan Pierrou, presented Alzinova at Redey's event in Gothenburg. Read more
Image for CEO Tord Labuda presented at Redeye Life Science day

2025-12-04

CEO Tord Labuda presented at Redeye Life Science day

Read more
Image for Alzinova at BIO-Europe

2025-11-04

Alzinova at BIO-Europe

This week, our Business Development Director Sebastian Hansson is representing Alzinova AB at BIO-Europe, one of Europe’s leading partnering… Read more
Image for CEO Tord Labuda participated in the Redeye Theme: Neurology event

2025-10-16

CEO Tord Labuda participated in the Redeye Theme: Neurology event

If you missed the live presentation, you can now watch it on demand via the link below. Read more
Image for Alzinova featured in Japanese media

2025-10-07

Alzinova featured in Japanese media

We’re pleased to share that Alzinova has been featured in a new Japanese article ahead of BioJapan 2025, where… Read more
Image for Our CEO interviewed by Alzheimerfonden

2025-09-30

Our CEO interviewed by Alzheimerfonden

CEO Tord Labuda, was recently interveiwed by Alzheimerfonden. Alzheimerfonden is the fundraising organisation in Sweden that contributes to research… Read more
Image for Presentation at BioStock’s Investing in Life Science

2025-09-26

Presentation at BioStock’s Investing in Life Science

CEO Tord Labuda presented at BioStock's Investing in Life Science – From Seed to Success in Stockholm. Read more
Image for Alzinova article published by UK analysts

2025-08-29

Alzinova article published by UK analysts

Read more
Image for Tord Labuda interviewed by BioStock

2025-08-25

Tord Labuda interviewed by BioStock

This interview highlights where Alzinova stands today and what lies ahead. Tord provides a clear overview of the company’s… Read more
Image for Carnegie Investment Bank interviews Alzinova

2025-06-24

Carnegie Investment Bank interviews Alzinova

Talking about key developments, the progress of ALZ-101, and what’s next as we prepare for Phase 2. Read more
Image for BioStock interviews our CEO on the path to Phase 2

2025-05-04

BioStock interviews our CEO on the path to Phase 2

As Alzinova advances toward Phase 2, CEO Tord Labuda shares his perspective on what sets the company apart in… Read more
Image for Podcast with CEO Tord Labuda

2025-04-30

Podcast with CEO Tord Labuda

In the latest episode of Småbolagspodden, CEO Tord Labuda shares insights into Alzinova’s work in developing a vaccine for… Read more
Image for Biostock interview with our CSO Anders Sandberg

2025-04-30

Biostock interview with our CSO Anders Sandberg

In a new article from BioStock, CSO Anders Sandberg discusses Alzinova’s unique research strategy and how ALZ-101 stands out… Read more
Image for Alzheimerloppet / Alzheimer Race 2025

2025-04-29

Alzheimerloppet / Alzheimer Race 2025

We are sponsoring Alzheimerloppet 2025, May 22–25. Read more
Image for Alzinova presented at Redeyes Theme Event: Alzheimer’s and Parkinson’s

2025-04-09

Alzinova presented at Redeyes Theme Event: Alzheimer’s and Parkinson’s

CEO Tord Labuda presented the latest company developments, including the positive final results from our Phase 1b study with… Read more
Image for Our CEO, Tord Labuda, interviewed by Carnegie

2025-03-31

Our CEO, Tord Labuda, interviewed by Carnegie

Read more
Image for Carnegie interview with our CEO

2024-12-18

Carnegie interview with our CEO

Our CEO Tord Labuda, was interview by Carnegie, discussing the latest clinical results for the Alzheimer's vaccine, partner plans,… Read more
Image for CEO interview by Redeye

2024-12-18

CEO interview by Redeye

Redeye interview with our CEO Tord Labuda. Read more
Image for Alzinova at Redeye Neurology Event 2024

2024-10-24

Alzinova at Redeye Neurology Event 2024

Tord Labuda, our CEO, presented at Redeye Neurology Event in Stockholm on October 23rd. Read more
Image for Interview with our new CEO

2024-10-23

Interview with our new CEO

Tord Labuda interviewed by Redeye analyst. Read more
Image for Meet our new CEO, Tord Labuda!

2024-10-11

Meet our new CEO, Tord Labuda!

In a recent interview with BioStock - Connecting Innovation and Capital, Tord shares insights into his extensive background in… Read more
Image for Successful visit to US BIO

2024-06-13

Successful visit to US BIO

Our Business Development Director, Sebastian Hansson, presented positive data from our phase 1b study with ALZ-101 to key players… Read more
Image for Alzinova at Aktiedagarna in Stockholm

2024-06-11

Alzinova at Aktiedagarna in Stockholm

CEO Kristina Torfgård presented Alzinova at Aktiespararnas' event Aktiedagarna. Read more
Image for Alzinova presented in investor pitch by BioStock

2024-06-11

Alzinova presented in investor pitch by BioStock

CEO Kristina Torfgård talks about the research results for the company's emerging candidate, the way forward and the ongoing… Read more
Image for Alzinova presented at Penser Access by Carnegie Healthcare webinar

2024-06-07

Alzinova presented at Penser Access by Carnegie Healthcare webinar

Read more
Image for Q&A session at Redeye with CEO Kristina Torfgård

2024-06-04

Q&A session at Redeye with CEO Kristina Torfgård

Read more
Image for Alzheimerloppet 2024

2024-05-29

Alzheimerloppet 2024

The team at Alzinova AB participated in this year's Alzheimer's run hosted by Alzheimerfonden. Read more
Image for BioStock interview with our CEO

2024-05-29

BioStock interview with our CEO

Kristina Torfgård, our CEO, comments on Alzinova’s lead candidate, ALZ-101, now in a higher dose. Read more
Image for Our BDD interviewed by BioStock

2024-05-23

Our BDD interviewed by BioStock

"We will be an obvious component in Big Pharma's Alzheimer's portfolio."… Read more
Image for Alzinova at the Redeye Investor Forum

2024-05-20

Alzinova at the Redeye Investor Forum

Did you miss last week’s presentation about Alzinova at the Redeye Investor Forum?… Read more
Image for Alzinova AB at BIO2024 in Boston

2024-05-13

Alzinova AB at BIO2024 in Boston

We're gearing up for an exhilarating experience!… Read more
Image for Kristina Torfgård our outgoing CEO comments on the company’s potential

2024-05-06

Kristina Torfgård our outgoing CEO comments on the company’s potential

Read more
Image for Our CSO, Anders Sandberg, comments on new assay data in BioStock interview

2024-04-23

Our CSO, Anders Sandberg, comments on new assay data in BioStock interview

Following our in-depth analysis of data from the initial phase Ib study, our analysis revealed that our vaccine candidate… Read more
Image for BioStock interview

2024-04-11

BioStock interview

As we could announce last week, all patients in the extension part (part B) of our phase 1b study,… Read more
Image for Redeye Alzheimer Event

2024-03-26

Redeye Alzheimer Event

Kristina Torfgård our CEO, presented Alzinova and participated in the panel discussion at Redeye Alzheimer Event in Stockholm. Read more